CBS-3595

CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808) -induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases[1].

Product Specifications

CAS Number

[908380-97-2]

UNSPSC

12352005

Target

P38 MAPK; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cbs-3595.html

Smiles

CC(NC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=C(S(C)=O)N2C)=C1)=O

Molecular Formula

C18H17FN4O2S

Molecular Weight

372.42

References & Citations

[1]Koch DA, et al. Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats. Rheumatology (Oxford) . 2014 Mar;53 (3) :425-32.